Found: 9
Select item for more details and to access through your institution.
International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis: A Step Toward Personalized Treatment.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Developing a Therapeutic Range of Adalimumab Serum Concentrations in Management of Psoriasis.
- Published in:
- JAMA Dermatology, 2015, v. 151, n. 6, p. 616, doi. 10.1001/jamadermatol.2014.5479
- By:
- Publication type:
- Article
Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one-year follow-up.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Extent and Consequences of Antibody Formation Against Adalimumab in Patients With Psoriasis One-Year Follow-up.
- Published in:
- JAMA Dermatology, 2014, v. 150, n. 2, p. 130, doi. 10.1001/jamadermatol.2013.8347
- By:
- Publication type:
- Article
Methotrexate Dosing Regimen for Plaque-type Psoriasis: A Systematic Review of the Use of Test-dose, Start-dose, Dosing Scheme, Dose Adjustments, Maximum Dose and Folic Acid Supplementation.
- Published in:
- Acta Dermato-Venereologica, 2016, v. 96, n. 1, p. 23, doi. 10.2340/00015555-2081
- By:
- Publication type:
- Article
Composition of Innate Lymphoid Cell Subsets in the Human Skin: Enrichment of NCR<sup>+</sup> ILC3 in Lesional Skin and Blood of Psoriasis Patients.
- Published in:
- Journal of Investigative Dermatology, 2014, v. 134, n. 9, p. 2351, doi. 10.1038/jid.2014.146
- By:
- Publication type:
- Article
Adalimumab combined with methotrexate versus adalimumab monotherapy in psoriasis: Three‐year follow‐up data of a single‐blind randomized controlled trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 9, p. 1815, doi. 10.1111/jdv.19089
- By:
- Publication type:
- Article
Cutaneous Toxicity After Chemoradiotherapy and PD‐L1 Inhibition in Two Patients with Esophageal Adenocarcinoma: More than Meets the Eye.
- Published in:
- Oncologist, 2019, v. 24, n. 4, p. e149, doi. 10.1634/theoncologist.2018-0674
- By:
- Publication type:
- Article